Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study

Emilio Iannitto; Simone Ferrero; Côme Bommier; Daniela Drandi; Martina Ferrante; Krimo Bouabdallah; Sylvain Carras; Guido Gini; Vincent Camus; Salvatrice Mancuso; Luigi Marcheselli; Angela Ferrari; Michele Merli; Benoit Tessoulin; Caterina Stelitano; Kheira Beldjord; Giovanni Roti; Fabrice Jardin; Barbara Castagnari; Francesca Palombi; Lucile Baseggio; Alexandra Traverse-Glehen; Claudio Tripodo; Anna Marina Liberati; Margherita Parolini; Sara Usai; Caterina Patti; Massimo Federico; Maurizio Musso; Marco Ladetto; Emanuele Zucca; Catherine Thieblemont

doi:10.3324/haematol.2023.284109

Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study

Emilio Iannitto
, Simone Ferrero
, Côme Bommier
, Daniela Drandi
, Martina Ferrante
, Krimo Bouabdallah
, Sylvain Carras
, Guido Gini
, Vincent Camus
, Salvatrice Mancuso
, Luigi Marcheselli
, Angela Ferrari
, Michele Merli
, Benoit Tessoulin
, Caterina Stelitano
, Kheira Beldjord
, Giovanni Roti
, Fabrice Jardin
, Barbara Castagnari
, Francesca Palombi

Lucile Baseggio, Alexandra Traverse-Glehen, Claudio Tripodo, Anna Marina Liberati, Margherita Parolini, Sara Usai, Caterina Patti, Massimo Federico, Maurizio Musso, Marco Ladetto, Emanuele Zucca, Catherine Thieblemont

Department of Translational Medicine

Research output: Contribution to journal › Letter › peer-review

Abstract

: Not available.

Original language	English
Pages (from-to)	2297-2302
Number of pages	6
Journal	Haematologica
Volume	109
Issue number	7
DOIs	https://doi.org/10.3324/haematol.2023.284109
Publication status	Published - Jul 2024

Access to Document

10.3324/haematol.2023.284109

Fingerprint

Dive into the research topics of 'Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study'. Together they form a unique fingerprint.

Cite this

Iannitto, E., Ferrero, S., Bommier, C., Drandi, D., Ferrante, M., Bouabdallah, K., Carras, S., Gini, G., Camus, V., Mancuso, S., Marcheselli, L., Ferrari, A., Merli, M., Tessoulin, B., Stelitano, C., Beldjord, K., Roti, G., Jardin, F., Castagnari, B., ... Thieblemont, C. (2024). Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study. Haematologica, 109(7), 2297-2302. https://doi.org/10.3324/haematol.2023.284109

@article{495cec426540415a85021c65fb75bbc8,

title = "Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study",

abstract = ": Not available.",

author = "Emilio Iannitto and Simone Ferrero and C{\^o}me Bommier and Daniela Drandi and Martina Ferrante and Krimo Bouabdallah and Sylvain Carras and Guido Gini and Vincent Camus and Salvatrice Mancuso and Luigi Marcheselli and Angela Ferrari and Michele Merli and Benoit Tessoulin and Caterina Stelitano and Kheira Beldjord and Giovanni Roti and Fabrice Jardin and Barbara Castagnari and Francesca Palombi and Lucile Baseggio and Alexandra Traverse-Glehen and Claudio Tripodo and Liberati, \{Anna Marina\} and Margherita Parolini and Sara Usai and Caterina Patti and Massimo Federico and Maurizio Musso and Marco Ladetto and Emanuele Zucca and Catherine Thieblemont",

year = "2024",

month = jul,

doi = "10.3324/haematol.2023.284109",

language = "English",

volume = "109",

pages = "2297--2302",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Ferrata Storti Foundation",

number = "7",

}

Iannitto, E, Ferrero, S, Bommier, C, Drandi, D, Ferrante, M, Bouabdallah, K, Carras, S, Gini, G, Camus, V, Mancuso, S, Marcheselli, L, Ferrari, A, Merli, M, Tessoulin, B, Stelitano, C, Beldjord, K, Roti, G, Jardin, F, Castagnari, B, Palombi, F, Baseggio, L, Traverse-Glehen, A, Tripodo, C, Liberati, AM, Parolini, M, Usai, S, Patti, C, Federico, M, Musso, M, Ladetto, M, Zucca, E & Thieblemont, C 2024, 'Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study', Haematologica, vol. 109, no. 7, pp. 2297-2302. https://doi.org/10.3324/haematol.2023.284109

Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study. / Iannitto, Emilio; Ferrero, Simone; Bommier, Côme et al.
In: Haematologica, Vol. 109, No. 7, 07.2024, p. 2297-2302.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma

T2 - long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study

AU - Iannitto, Emilio

AU - Ferrero, Simone

AU - Bommier, Côme

AU - Drandi, Daniela

AU - Ferrante, Martina

AU - Bouabdallah, Krimo

AU - Carras, Sylvain

AU - Gini, Guido

AU - Camus, Vincent

AU - Mancuso, Salvatrice

AU - Marcheselli, Luigi

AU - Ferrari, Angela

AU - Merli, Michele

AU - Tessoulin, Benoit

AU - Stelitano, Caterina

AU - Beldjord, Kheira

AU - Roti, Giovanni

AU - Jardin, Fabrice

AU - Castagnari, Barbara

AU - Palombi, Francesca

AU - Baseggio, Lucile

AU - Traverse-Glehen, Alexandra

AU - Tripodo, Claudio

AU - Liberati, Anna Marina

AU - Parolini, Margherita

AU - Usai, Sara

AU - Patti, Caterina

AU - Federico, Massimo

AU - Musso, Maurizio

AU - Ladetto, Marco

AU - Zucca, Emanuele

AU - Thieblemont, Catherine

PY - 2024/7

Y1 - 2024/7

N2 - : Not available.

AB - : Not available.

UR - https://www.scopus.com/pages/publications/85197962833

U2 - 10.3324/haematol.2023.284109

DO - 10.3324/haematol.2023.284109

M3 - Letter

SN - 0390-6078

VL - 109

SP - 2297

EP - 2302

JO - Haematologica

JF - Haematologica

IS - 7

ER -

Iannitto E, Ferrero S, Bommier C, Drandi D, Ferrante M, Bouabdallah K et al. Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study. Haematologica. 2024 Jul;109(7):2297-2302. doi: 10.3324/haematol.2023.284109

Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study

Abstract

Access to Document

Other files and links

Fingerprint

Cite this